CN106689698B - 一种奶牛产后灌服营养补充剂及其生产方法 - Google Patents
一种奶牛产后灌服营养补充剂及其生产方法 Download PDFInfo
- Publication number
- CN106689698B CN106689698B CN201710096157.2A CN201710096157A CN106689698B CN 106689698 B CN106689698 B CN 106689698B CN 201710096157 A CN201710096157 A CN 201710096157A CN 106689698 B CN106689698 B CN 106689698B
- Authority
- CN
- China
- Prior art keywords
- parts
- postpartum
- formula
- propylene glycol
- cattle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title abstract description 11
- 235000013336 milk Nutrition 0.000 title description 4
- 239000008267 milk Substances 0.000 title description 4
- 210000004080 milk Anatomy 0.000 title description 4
- 241000283690 Bos taurus Species 0.000 claims abstract description 118
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 69
- 235000013365 dairy product Nutrition 0.000 claims abstract description 53
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 24
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 17
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 17
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 17
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 17
- 230000001605 fetal effect Effects 0.000 claims abstract description 16
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000004330 calcium propionate Substances 0.000 claims abstract description 12
- 235000010331 calcium propionate Nutrition 0.000 claims abstract description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 12
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 12
- 239000001103 potassium chloride Substances 0.000 claims abstract description 12
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 244000309466 calf Species 0.000 claims abstract description 10
- 210000004767 rumen Anatomy 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 230000032696 parturition Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000013589 supplement Substances 0.000 abstract description 7
- 238000011084 recovery Methods 0.000 abstract description 6
- 208000021129 Postpartum disease Diseases 0.000 abstract description 4
- 238000003973 irrigation Methods 0.000 abstract description 4
- 230000002262 irrigation Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 1
- 239000003674 animal food additive Substances 0.000 abstract 1
- 229940041514 candida albicans extract Drugs 0.000 abstract 1
- 239000012138 yeast extract Substances 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 30
- 239000011575 calcium Substances 0.000 description 30
- 229910052791 calcium Inorganic materials 0.000 description 30
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 26
- 208000013038 Hypocalcemia Diseases 0.000 description 13
- 230000000705 hypocalcaemia Effects 0.000 description 13
- 208000007976 Ketosis Diseases 0.000 description 11
- 230000004140 ketosis Effects 0.000 description 11
- 208000019025 Hypokalemia Diseases 0.000 description 10
- 206010033799 Paralysis Diseases 0.000 description 10
- 208000024896 potassium deficiency disease Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 210000003165 abomasum Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000009984 peri-natal effect Effects 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000035563 calcemia Effects 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001184 hypocalcaemic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022676 rumination Effects 0.000 description 2
- 208000015212 rumination disease Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-IGMARMGPSA-N Calcium-40 Chemical compound [40Ca] OYPRJOBELJOOCE-IGMARMGPSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940080286 lowsium Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229940070017 potassium supplement Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种奶牛产后灌服营养补充剂及其生产方法，涉及奶牛分娩营养补充剂领域，特别是涉及一种奶牛产后灌服营养补充剂及其生产方法。本发明根据头胎牛与经产牛生理特点将配方区分设计，两者共同组分中包括如下重量份的组分：过瘤胃烟酸1‑10份、氯化钾1‑20份、硫酸镁1‑20份、综合料1‑10份、氯化钠1‑10份、啤酒酵母提取物1‑10份，除共同组分外，头胎牛配方还包括固体丙二醇10‑100份，经产牛配方还包括固体丙二醇10‑20份、丙酸钙10‑100份。通过上述方式，本发明能够及时补充奶牛分娩后所需的营养物质，降低产后各类疾病的发病率，促进奶牛产后体况恢复，最终降低牧场经营成本，提高牧场的经济效应。
Description
技术领域
本发明涉及奶牛分娩营养补充剂领域，特别是涉及一种奶牛产后灌服营养补充剂及其生产方法。
背景技术
近些年，我国奶业养殖业发展迅速，养殖规模不断扩大，但养殖过程中存在诸多问题，极为影响奶牛的健康和牧场的收益。这其中，奶牛分娩前后，经历了巨大的生理和代谢变化及一系列应激，发生疾病的几率大大增加，因此奶牛分娩前后的护理是牧场管理的关键环节，对奶牛健康和牧场的经济收益占据举足轻重的作用。
奶牛分娩前后，血钙大量进入初乳，且动用骨钙的能力降低，导致血钙迅速降低，若机体的钙没有得到及时的补充引发低血钙症，并容易诱发产后瘫痪、胎衣不下等疾病。
此外，由于妊娠后期胎儿和羊水挤占了大部分腹腔，挤压胃肠器官，致使奶牛消化道功能和食欲明显下降。奶牛分娩后由于食欲不足，体况虚弱，干物质采食量不足，能量负平衡引起体脂动员，造成肝脏脂肪沉积形成脂肪肝和酮体大量生成形成酮病。各种微量元素和维生素摄入不足，导致对各种疾病抵抗力降低。同时子宫压力突然释去，瘤胃空虚，给腹腔留下过大空间，而真胃的悬韧带由于钙离子的流失，失去收缩力，便被压到瘤胃左方，置于左腹壁与瘤胃之间。代谢失调，胃运动减弱，真胃不能及时收缩回位，导致真胃移位。
目前国内牧场多采用产后灌服丙二醇，氯化钙等组合物措施应对，然而牧场自主配置的灌服组合物缺乏科学论证和合理配比。而市场上出售的商品化灌服剂未针对头胎牛和经产牛的生理特点分别设计，头胎牛血钙和骨钙充足，不需要补充钙，补充了反而易增加奶牛心脏负担，而经产牛血钙和骨钙不足，则需要大量补充钙，没有区分设计则效果参差不齐。且现有灌服多为液体或需要配合液体包使用，运输储存等存在不便。
鉴于奶牛养殖业的发展现状，急需开发一种可针对奶牛生理特点而设计的，可产业化应用的营养补充剂。
发明内容
本发明主要解决的技术问题是提供一种奶牛产后灌服营养补充剂，能够及时补充奶牛产后所需的各种营养物质，预防奶牛低血钙症、低钾血症、产后瘫痪、酮病、脂肪肝、真胃变位等围产期代谢病，预防产后脱水和食欲不振，促进奶牛产后采食，维持奶牛产后瘤胃内环境，改善能量和葡萄糖代谢，缓解分娩应激，促进产后体况恢复，降低生产成本，提高牧场效益，本发明的另一个目的是提供一种奶牛产后灌服营养补充剂的生产方法。
为解决上述技术问题，本发明采用的一个技术方案是：提供一种奶牛产后灌服营养补充剂；根据头胎牛与经产牛的不同生理特点区分设计配方，两个配方的共同组分包括如下重量份的组分：
| 过瘤胃烟酸 | 1-10份 | 综合料 | 1-10份 |
| 氯化钾 | 1-20份 | 氯化钠 | 1-10份 |
| 硫酸镁 | 1-20份 | 酵母粉 | 1-10份 |
除共同组分外，头胎牛配方还包括如下重量份的组分：
固体丙二醇(40％)：10-100份
除共同组分外，经产牛配方还包括如下重量份的组分：
固体丙二醇(40％)：10-20份，丙酸钙10-100份
所述的奶牛产后灌服营养补充剂，优选如下重量份的组分：
| 过瘤胃烟酸 | 2-5份 | 综合料 | 1-3份 |
| 氯化钾 | 10-15份 | 氯化钠 | 3-7份 |
| 硫酸镁 | 10-15份 | 酵母粉 | 2-5份 |
除共同组分外，优选地，头胎牛配方还包括如下重量份的组分：
固体丙二醇(40％)：50-70份
除共同组分外，优选地，经产牛配方还包括如下重量份的组分：
固体丙二醇(40％)：12-18份，丙酸钙40-70份
所述的奶牛产后灌服营养补充剂，优选如下重量份的组分：
| 过瘤胃烟酸 | 2份 | 综合料 | 1份 |
| 氯化钾 | 12.5份 | 氯化钠 | 5份 |
| 硫酸镁 | 12.5份 | 酵母粉 | 2份 |
除共同组分外，优选地，头胎牛配方包括如下重量份的组分：
固体丙二醇(40％含量)：65份
除共同组分外，优选地，经产牛配方包括如下重量份的组分：
固体丙二醇(40％含量)：15份，丙酸钙50份
所述的综合料中，每千克综合料包含维生素B6600mg-1400mg，维生素B128mg-12mg，维生素C 7g-13g，维生素D3250万IU-450万IU，维生素E 8万IU-12万IU，生物素1500mg-2500mg，叶酸1500mg-2500mg，铜27000mg-37000mg，铁15000mg-25000mg，锌90000mg-150000mg，锰40000mg-60000mg，碘600mg-1400mg(北京东方天合生物技术有限责任公司代购原料并加工生产)。
所述的过瘤胃烟酸，每千克过瘤胃烟酸包含烟酸400g-500g，棕榈脂肪粉400g-500g，羧甲基纤维素钠1g-10g，淀粉10g-100g，糊精10g-20g。通过包被技术，烟酸可被奶牛高效吸收，促进奶牛产后采食，并降低奶牛患酮病和脂肪肝的概率(北京东方天合生物技术有限责任公司代加工并生产)。
本发明中添加的氯化钾，用于维持奶牛产后的血液中的钾的水平，预防奶牛低钾血症及由低钾血症引起的奶牛产后瘫痪。
本发明中添加的氯化钠，对促进电解质代谢平衡、体液代谢平衡，缓解分娩应激起到了促进作用。
本发明中添加的酵母粉，通过改善瘤胃微生物区系和活性，增加奶牛产后采食量和小肠对饲料的消化吸收。
硫酸镁用于维持奶牛产后血液中镁的水平，镁具有诸多生理功能，它是机体代谢酶的重要辅酶，在机体代谢活动中发挥重要作用。奶牛产后血液中的镁含量较低，需补充镁预防低镁血症。同时，镁还具有促进机体钙吸收的功能，有助于提高血钙水平。
本发明中采用的固体丙二醇，便于产品整体设计为固体粉末态，方便运输和存储。丙二醇进入瘤胃后，一部分迅速被瘤胃壁吸收，另一部分代谢为丙酸盐后被吸收，吸收的丙酸盐和丙二醇经血液循环进入肝脏，经葡萄糖异生转化为葡萄糖，改善能量供应，避免了因血糖降低导致的体脂动员，从而降低脂肪肝和酮病的发生概率。
丙酸钙在Mg离子的协助下可高效补充血钙，弥补产后牛血钙的不足，极大程度地减少低血钙症的发生，预防产后瘫痪，且丙酸盐作为生糖前体，在体内可通过糖异生途径生成葡萄糖，补充能量，避免了因血糖降低导致的体脂动员，从而降低脂肪肝和酮病的发生概率。
所述的奶牛产后灌服营养补充剂，根据头胎牛与经产牛的不同生理特点区分设计配方，由于头胎牛产后血钙和骨钙含量充足，不需要补钙，大量补钙反而加重奶牛心脏负担。而经产牛产后血钙和骨钙含量不足，需大量补钙。头胎牛配方与经产牛配方中不同的丙二醇和丙酸钙含量的设计，可针对头胎牛生理特点只补充能量，经产牛配方则兼顾补充能量和补钙。
本发明通过20升温水溶解为奶牛灌服后，为新产奶牛及时补充营养物质，调节瘤胃内环境，促进奶牛采食，预防奶牛产后低血钙症、低钾血症、产后瘫痪、酮病、脂肪肝、真胃变位等围产期代谢病，缓解分娩应激，促进产后体况恢复，降低牧场经营成本，提高牧场的经济效应。
本发明的另一个目的是提供上述奶牛产后灌服营养补充剂的生产方法，步骤如下：
(1).按照配方准确称量各种组分的原料；
(2).将综合料的组分进行预混合，使用VH-100型混合机(莱州市诺贝尔化工机械厂)常温下混合10-20min，使之混合均匀；
(3).投料混合：
a.头胎牛配方：先投10-50份重量份的固体丙二醇进SLHYS-500型双轴桨叶混合机(廊坊燕北畜牧机械集团有限公司)中，然后不分先后投入预混合好的综合料，过瘤胃烟酸，氯化钠，氯化钾，硫酸镁，最后再投剩余的固体丙二醇，投料过程中边投料边混合，投完最后一个组分后，定时混合2-5min；
b.经产牛配方：先投10-50份重量份的丙酸钙进SLHYS-500型双轴桨叶混合机(廊坊燕北畜牧机械集团有限公司)中，然后不分先后投入预混合好的综合料，过瘤胃烟酸，氯化钠，氯化钾，硫酸镁，固体丙二醇，最后再投剩余的丙酸钙，投料过程中边投料边混合，投完最后一个组分后，定时混合2-5min；
(4).将混合好的物料装入小包装袋中(每袋一公斤)；
(5).将装有物料的小包装袋内的空气放净，再用连续封口机进行封口。
具体实施方式
以下对本发明的优选实施例进行说明，应当理解，此处所描述的优选实施例仅用于说明和解释本发明，并不用于限定本发明。此外应理解，在阅读了本发明讲授的内容后，本领域技术人员可以对本发明做各种修改和改动，这些等价形式同样落于本申请所附权利要求书所限定的范围
实施例
表1实施例组分
将上述实施例中各组分按照所述生产方法制作，即可得到本发明奶牛产后灌服营养补充剂，以上均为重量份。上述中各组分原料均为饲料级，且均为常规市售产品，信息如下：
氯化钾：广州庞顺饲料有限公司；
氯化钠：中盐枣阳盐化有限公司
硫酸镁：莱州市莱玉化工有限公司；
过瘤胃烟酸：北京东方天合生物技术有限责任公司加工并生产；
综合料：北京东方天合生物技术有限责任公司代购原料并加工生产；
酵母粉：广东益鲜美生物科技有限公司；
固体丙二醇：上海鼎牛饲料有限公司；
丙酸钙：山东同泰微润化工有限公司；
效果实施例：
试验在北京首农畜牧发展有限公司长阳四场进行，选择80头围产期奶牛，其中青年牛、经产牛各40头。按照年龄、胎次、分娩时间相近的原则分为对照组、试验组、阳性对照一组、阳性对照二组，每组各20头，常规饲养管理，每日饲喂三次，自由饮水。各组奶牛使用相同日粮，试验组在奶牛分娩后30min内将实施例1制得的奶牛产后灌服营养补充剂1kg用20L温水溶解，对一头奶牛进行一次性灌服，对照组灌服温水20L，阳性对照组分别使用进口产品1和2灌服。
试验期间定时检测奶牛血钙、血钾、B-羟丁酸等血液指标，记录两组奶牛产后瘫痪、酮病、真胃变位等发病情况，对数据进行分类统计后使用SPSS18.0进行统计分析。试验数据统计结果见表2-表8。
从上述实施例的效果来看，使用本发明的奶牛产后灌服营养补充剂，可预防产后瘫痪、低钾血症、酮病、真胃变位等产后疾病，促进奶牛产后生理状态的恢复，从而降低产后疾病发生及淘汰比例。
表2试验牛围产期数据
所有参试牛产前7天时，仅有一头经产牛出现产前亚临床低血钙(iCa为1.03mmol/L)，并且在产犊0h时血钙正常，表明荷斯坦奶牛产前亚临床低血钙的比例极低，并且不需要人为干预。产后3天内所有参试的80头奶牛均未发生产后瘫痪。产后0h所有头胎牛血钙水平均正常，从后续监测数据来看，仅有1头头胎牛在产后12h时血钙降至0.98mmol/L，但未表现产后瘫痪，随后在产后24h恢复正常。产后24小时内荷斯坦头胎牛亚临床低血钙发病率为2.5％，产后瘫痪的发病率为0％，表明荷斯坦头胎牛不需要产后口服补钙处理，本发明中头胎牛配方不含钙离子是正确的。
表3围产期奶牛亚临床低血钙发病情况
产后0小时，总计25头经产牛出现亚临床低血钙，经产牛分娩时亚临床低血钙的发病率为62.5％(25/40)。产后0-24小时，总计30头经产牛出现亚临床低血钙，其中产后0小时发病25头，产后6小时发病头4，产后24小时发病1头，经产牛产后24小时内亚临床低血钙的发病率为75％(30/40)。产后6-24小时仍有新发的亚临床低血钙牛出现，与产后初乳钙流失导致血钙下降及奶牛自身血钙调节机制滞后有关。
表4经产牛产后24h亚临床低血钙恢复情况
从产后血钙恢复时间看(表4)，对照组亚临床低血钙奶牛在产后24小时时仍有50％的奶牛血钙未能恢复正常水平。而产后经口补钙的经产牛，在产后24小时73.68％的亚临床低血钙奶牛血钙恢复正常。从效果看，试验组奶牛产后24h内无新发病例出现，效果优于进口产品。
表5产后亚临床低钾血症情况
*此数值主要为头胎牛产后12h高发(头胎牛在产后12h一个时间点新出现8头亚临床低血钾)。
血液中钾离子含量与采食量、饲料中粗饲料(富钾)比例、反刍及唾液分泌、机体酸碱平衡、相关离子的竞争性吸收等因素相关。在产犊前后由于分娩应激影响干物质采食量及反刍情况，奶牛极易出现低钾血症。试验数据表明，78.75％(63/80)的奶牛在产前7天至产后5天内会出现亚临床低钾血症，其中产前7天及产后0小时的发病率低，仅为11.25％和16.25％，而产后1天内及产后5天时的发病率高达55％(44/80)。试验组产后立即口服补钾对缓解产后1天及产后5天时的亚临床低钾血症有很好的作用。
表6围产期经产牛血糖水平变化
表7围产期酮病发病情况(亚临床/临床)
*此数值为定期血酮检测检出的酮病牛数量
由于产犊需要大量耗能，奶牛在分娩时会动员大量能量，造成产后0小时血糖水平急剧升高，而后逐渐回落至正常范围。产后6小时、12小时和24小时分别有5头、2头、3头奶牛出现低血糖全为头胎牛发生(9/10)，这可能与胰岛素的耐受性有关。将经产牛单独分析可以看出，本发明提升血糖、稳定β-羟丁酸的功能优于进口产品，可有效预防产后低血糖及酮病的发生。
表8产后60天内发病及淘汰情况
试验组奶牛产后60天发病率及淘汰率低于对照组及阳性对照组。可以看出，本发明可有效降低奶牛产后疾病发病率和淘汰率，效果优于进口产品。
Claims (2)
1.一种奶牛产后灌服营养补充剂；其特征在于，根据头胎牛与经产牛的不同生理特点区分为头胎牛配方和经产牛配方，其中，所述头胎牛配方由如下重量份的组分组成：
过瘤胃烟酸 2-5份； 综合料 1-3份；
氯化钾 10-15份； 氯化钠 3-7份；
硫酸镁 10-15份； 酵母粉 2-5份；
固体丙二醇 50-70份；
所述经产牛配方由如下重量份的组分组成：
过瘤胃烟酸 2-5份； 综合料 1-3份；
氯化钾 10-15份； 氯化钠 3-7份；
硫酸镁 10-15份； 酵母粉 2-5份；
固体丙二醇 12-18份； 丙酸钙 40-70份；
其中，每千克所述综合料包含维生素B6 600mg-1400mg，维生素B12 8mg-12mg，维生素C7g-13g，维生素D3 2500万IU-450万IU，维生素E 8万IU-12万IU，生物素1500mg-2500mg，叶酸1500mg-2500mg，铜27000mg-37000mg，铁15000mg-25000mg，锌90000mg-50000mg，锰40000mg-60000mg，碘600mg-1400mg；
其中，每千克所述过瘤胃烟酸包含烟酸400g-500g，棕榈脂肪粉400g-500g，羧甲基纤维素钠1g-10g，淀粉10g-100g，糊精10g-20g。
2.根据权利要求1所述的一种奶牛产后灌服营养补充剂，其特征在于，所述头胎牛配方由如下重量份的组分组成：
过瘤胃烟酸 2份； 综合料 1份；
氯化钾 12.5份； 氯化钠 5份；
硫酸镁 12.5份； 酵母粉 2份；
固体丙二醇 65份；
所述经产牛配方由如下重量份的组分组成：
过瘤胃烟酸 2份； 综合料 1份；
氯化钾 12.5份； 氯化钠 5份；
硫酸镁 12.5份； 酵母粉 2份；
固体丙二醇 15份； 丙酸钙 50份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710096157.2A CN106689698B (zh) | 2017-02-22 | 2017-02-22 | 一种奶牛产后灌服营养补充剂及其生产方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710096157.2A CN106689698B (zh) | 2017-02-22 | 2017-02-22 | 一种奶牛产后灌服营养补充剂及其生产方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106689698A CN106689698A (zh) | 2017-05-24 |
| CN106689698B true CN106689698B (zh) | 2021-02-26 |
Family
ID=58917288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710096157.2A Active CN106689698B (zh) | 2017-02-22 | 2017-02-22 | 一种奶牛产后灌服营养补充剂及其生产方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106689698B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107691832A (zh) * | 2017-10-18 | 2018-02-16 | 河南农业大学 | 一种用于奶牛产后恢复的复合饲料添加剂及其制备方法 |
| CN108740399A (zh) * | 2018-08-22 | 2018-11-06 | 天津市畜牧兽医研究所 | 一种用于奶牛产后灌服的复合预混合饲料及其应用 |
| CN111248343A (zh) * | 2018-12-03 | 2020-06-09 | 中粮集团有限公司 | 营养补充剂及其应用以及动物饲料 |
| CN111670864B (zh) * | 2020-07-09 | 2021-11-23 | 河北冀丰动物营养科技有限责任公司 | 一种提升围产期奶牛健康的饲养方法 |
| CN112825969A (zh) * | 2021-03-03 | 2021-05-25 | 四川新希望华西牧业有限公司 | 奶牛产后灌服用营养组合物以及奶牛产后营养灌服液 |
| US20230248761A1 (en) * | 2022-02-10 | 2023-08-10 | Contract Manufacturing Services, LLC | Method for supporting normal blood calcium concentrations in mammals |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1618316A (zh) * | 2003-11-19 | 2005-05-25 | 福建农林大学 | 奶牛热应激缓解剂及其制备方法和应用 |
| CN101305774A (zh) * | 2008-07-03 | 2008-11-19 | 河南花花牛奶牛育种科技有限公司 | 奶牛围产期复合营养补充剂 |
| CN101961078A (zh) * | 2010-10-22 | 2011-02-02 | 天津嘉立荷饲料有限公司 | 一种奶牛产后瘤胃灌服饲料 |
| CN103340317A (zh) * | 2013-07-15 | 2013-10-09 | 长春博瑞饲料集团有限公司 | 一种奶牛产后灌服营养补充剂及其使用方法 |
-
2017
- 2017-02-22 CN CN201710096157.2A patent/CN106689698B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1618316A (zh) * | 2003-11-19 | 2005-05-25 | 福建农林大学 | 奶牛热应激缓解剂及其制备方法和应用 |
| CN101305774A (zh) * | 2008-07-03 | 2008-11-19 | 河南花花牛奶牛育种科技有限公司 | 奶牛围产期复合营养补充剂 |
| CN101961078A (zh) * | 2010-10-22 | 2011-02-02 | 天津嘉立荷饲料有限公司 | 一种奶牛产后瘤胃灌服饲料 |
| CN103340317A (zh) * | 2013-07-15 | 2013-10-09 | 长春博瑞饲料集团有限公司 | 一种奶牛产后灌服营养补充剂及其使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| 《过瘤胃保护烟酸对奶牛生产性能的影响及经济效益分析》;赵术帆等;《饲料饲养》;20121130(第11期);第10页右栏第1段、第11页左栏第1-2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106689698A (zh) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106689698B (zh) | 一种奶牛产后灌服营养补充剂及其生产方法 | |
| US10967002B2 (en) | Animal feed supplement and method | |
| CN103284002B (zh) | 一种母猪围产期浓缩饲料 | |
| CN102415505B (zh) | 高产奶牛泌乳期功能性颗粒饲料 | |
| CN101836699B (zh) | 一种保护奶牛安全度过围产后期的奶牛灌服液 | |
| CN103340317A (zh) | 一种奶牛产后灌服营养补充剂及其使用方法 | |
| CN101406166A (zh) | 仔猪早期隔离断奶方法 | |
| CN105581302B (zh) | 一种提供产妇分娩所需能量的果冻及其制备方法 | |
| CN110800872A (zh) | 一种繁殖母羊无草饲喂饲料及其制备方法 | |
| CN107319163A (zh) | 哺乳母猪配合饲料及其制备和使用方法 | |
| CN101473900A (zh) | 仔猪断奶全价配合饲料 | |
| CN105685464A (zh) | 一种奶牛饲料添加剂及围产前期奶牛的饲养方法 | |
| CN107647146A (zh) | 一种头胎母猪营养强化剂及其制备和使用方法 | |
| CN106912689A (zh) | 一种妊娠期饲料添加剂及饲料 | |
| CN103250883A (zh) | 提高肉用种兔繁殖性能的饲料 | |
| CN108077622B (zh) | 一种提高母猪生产性能的添加剂及其制备方法和包含其的混合饲料 | |
| CN106889327A (zh) | 一种乳猪奶粉及其制备方法 | |
| CN105850871A (zh) | 一种提高波尔山羊产羔率的养殖方法 | |
| CN104171455A (zh) | 奶牛全混合日粮配方及其饲养技术 | |
| CN108991240A (zh) | 一种奶牛泌乳期精料补充料及其制备方法 | |
| CN108684954A (zh) | 一种提高泌乳量的哺乳母猪配合饲料及其制备方法 | |
| CN111000889B (zh) | 一种用于生产母猪饲料的中药组合物 | |
| CN113693166A (zh) | 一种奶牛专用分段式缓释矿物元素棒及其制备方法 | |
| CN113287685A (zh) | 一种奶牛干奶围产期精料补充料及其制备工艺 | |
| CN111972553A (zh) | 一种围产期奶牛营养补充料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210412 Address after: 233700 intersection of No.12 road and Chuangye Avenue, Tongling modern industrial park, Guzhen County, Bengbu City, Anhui Province Patentee after: ANHUI BEIJING ORIENTAL KINGHERD BIOTECHNOLOGY Co.,Ltd. Address before: 100193 No. 2 Old Summer Palace West Road, Beijing, Haidian District Patentee before: Cao Jie |
|
| TR01 | Transfer of patent right |